|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2007-12-6
|
|
pubmed:abstractText |
The effect of adalimumab on patient-reported outcomes (PROs) was evaluated in patients with moderate to severe psoriasis during the initial 16-week, double-blind period of a 52-week, Phase III, multicenter trial.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0954-6634
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
18
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
341-50
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:18058494-Adult,
pubmed-meshheading:18058494-Analysis of Variance,
pubmed-meshheading:18058494-Anti-Inflammatory Agents,
pubmed-meshheading:18058494-Antibodies, Monoclonal,
pubmed-meshheading:18058494-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:18058494-Double-Blind Method,
pubmed-meshheading:18058494-Female,
pubmed-meshheading:18058494-Health Status Indicators,
pubmed-meshheading:18058494-Humans,
pubmed-meshheading:18058494-Male,
pubmed-meshheading:18058494-Middle Aged,
pubmed-meshheading:18058494-Psoriasis,
pubmed-meshheading:18058494-Quality of Life,
pubmed-meshheading:18058494-Questionnaires,
pubmed-meshheading:18058494-Skin,
pubmed-meshheading:18058494-Treatment Outcome,
pubmed-meshheading:18058494-Tumor Necrosis Factor-alpha
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.
|
|
pubmed:affiliation |
Center for Health Outcomes Research, United BioSource Corporation, 7101 Wisconsin Avenue, Bethesda, MD 20814, USA. dennis.revicki@unitedbiosource.com
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Multicenter Study,
Clinical Trial, Phase III
|
